NOTE 8 – SUBSEQUENT EVENTS

On February 14, 2017, the Company announced that, for strategic reasons, it has paused enrollment in the clinical trial of its lead drug candidate squalamine lactate ophthalmic solution, 0.2%, for the treatment of neovascular age-related macular degeneration (wet AMD). The enrollment pause is not related to any safety issue. Currently, there are more than 200 subjects enrolled in the study. The study remains double-masked and no interim efficacy or futility analysis has been performed. Subjects currently enrolled in the study continue to undergo scheduled visits and assessments as well as receive assigned study treatments as per the current protocol.